文献速递胸部肿瘤放疗

局部晚期非小细胞肺癌同步及巩固卡铂联合白蛋白结合型或溶剂型紫杉醇

Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-06

这项多中心1/2期随机试验在不可手术的IIIA/B期非小细胞肺癌患者中,比较胸部放疗同步及巩固卡铂联合溶剂型紫杉醇(sb-paclitaxel)或白蛋白结合型紫杉醇(nab-paclitaxel)的疗效与毒性。2期队列中,sb-paclitaxel组与nab-paclitaxel组的2年总生存率分别为67%和56%(P=.10),无进展生存率分别为44%和27%(P=.14)。nab-paclitaxel组完成巩固治疗的患者比例更低(26% vs 58%,P=.005),3级及以上不良事件更常见(56% vs 30%,P=.029)。

要点

  • 2年总生存率sb-paclitaxel组67% vs nab-paclitaxel组56%(P=.10),无进展生存率44% vs 27%(P=.14)
  • 完成巩固治疗者nab-paclitaxel组26% vs sb-paclitaxel组58%(P=.005)
  • 3级及以上不良事件nab-paclitaxel组56% vs sb-paclitaxel组30%(P=.029)

核心结论

  • 在局部晚期非小细胞肺癌中,胸部放疗联合nab-paclitaxel的毒性高于sb-paclitaxel,疗效在数值上低于sb-paclitaxel。

研究设计与样本

  • 多中心1/2期随机临床试验,纳入不可手术的IIIA/B期非小细胞肺癌(AJCC第7版)且美国东部肿瘤协作组体力状态评分为0-1的患者。
  • 1期6例患者接受每周nab-paclitaxel 50 mg/m²联合卡铂AUC 2及同步胸部放疗60 Gy/30次,随后接受nab-paclitaxel 100 mg/m²(第1、8、15天)联合卡铂AUC 6(第1天)共2个21天周期。
  • 2期92例患者随机接受每周sb-paclitaxel 50 mg/m²或nab-paclitaxel 40 mg/m²联合同步放疗,随后接受sb-paclitaxel或nab-paclitaxel联合卡铂巩固治疗2个周期。

主要发现

  • 1期2例患者出现剂量限制性毒性,据此将2期nab-paclitaxel剂量定为40 mg/m²。
  • 2期队列2年总生存率sb-paclitaxel组67% vs nab-paclitaxel组56%(P=.10),无进展生存率sb-paclitaxel组44% vs nab-paclitaxel组27%(P=.14)。
  • 完成巩固治疗的患者比例nab-paclitaxel组26% vs sb-paclitaxel组58%(P=.005)。
  • 3级及以上不良事件发生率nab-paclitaxel组56% vs sb-paclitaxel组30%(P=.029)。

关键数值与推荐

  • 2期nab-paclitaxel剂量为40 mg/m²,系1期2例患者出现剂量限制性毒性后确定。
  • 1期方案为每周nab-paclitaxel 50 mg/m²联合卡铂AUC 2及同步胸部放疗60 Gy/30次。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the efficacy and toxicity of thoracic radiation therapy (RT) plus concurrent and consolidation carboplatin with either solvent-based paclitaxel (sb-paclitaxel) or solvent-free nanoparticle albumin-bound paclitaxel (nab-paclitaxel). METHODS AND MATERIALS: This multicenter phase 1/2 randomized trial included patients with inoperable stage IIIA/B nonsmall cell lung cancer (AJCC 7) and an Eastern Cooperative Oncology Group performance status of 0-1. In phase 1, 6 patients received weekly nab-paclitaxel (50 mg/m²) and carboplatin (AUC 2) with concurrent thoracic RT (60 Gy in 30 fractions), followed by nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 and carboplatin (AUC 6) on day 1 for two 21-day cycles. In phase 2, 92 patients were randomly assigned to weekly sb-paclitaxel (50 mg/m²) or nab-paclitaxel (40 mg/m²) with concurrent RT, followed by consolidation therapy with sb-paclitaxel or nab-paclitaxel and carboplatin for 2 cycles. RESULTS: Two phase 1 patients had dose-limiting toxicities, setting the phase 2 nab-paclitaxel dose at 40 mg/m². For the phase 2 cohort, 2-year overall survival was 67% for sb-paclitaxel and 56% for nab-paclitaxel (P = .10), with progression-free survival of 44% and 27%, respectively (P = .14). Fewer patients completed consolidation with nab-paclitaxel (26%) versus sb-paclitaxel (58%) (P = .005). Grade 3 and higher adverse events were more frequent with nab-paclitaxel (56%) than with sb-paclitaxel (30%) (P = .029). CONCLUSIONS: Nab-paclitaxel was associated with higher toxicity and numerically lower efficacy than sb-paclitaxel when used with thoracic radiation in locally advanced nonsmall cell lung cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Laine AM, Iyengar P, et al. Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 39922319. doi:10.1016/j.ijrobp.2025.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。